Pancreatic Cancer Pipeline Insight | Key Companies – FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical, and Others

Pancreatic Cancer Pipeline Insight | Key Companies - FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical, and Others

DelveInsight’s, “Pancreatic Cancer Pipeline Insight 2023” report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including Pancreatic Cancer clinical trials and nonclinical stage products. It also covers the Pancreatic Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Pancreatic Cancer Pipeline Report

 

  • DelveInsight’s Pancreatic Cancer Pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.

 

  • The leading Pancreatic Cancer Companies include ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others

 

  • Promising Pancreatic Cancer Pipeline Therapies include Pembrolizumab, Talazoparib, ODM-208, ZEN 3694, EPI-7386, RV 001, Adavosertib, Capivasertib, ADXS31-142, TRC253, Nivolumab, LAE001, BR55, ARV-110, Tazemetostat, REGN5678, VERU-111, Abemaciclib, Cabozantinib, LY01005, Tarlatamab, VT-464, BAY2315497, NX-1207, MBM-02, TAVT-45, FOR46, JNJ-78278343, 64Cu-SAR-bisPSMA, DKN-01, HC-1119, ChAdOx1-MVA 5T4, Onvansertib, GT0918, TNB-585, JANX007, 225Ac-PSMA I&T, CRB-701, BXCL701, AsiDNA, ADXS-504, HB-300, NUV-868, ARX517, JMKX002992, Zilovertamab, IMU-935, BNT112, and others.

 

  • The Pancreatic Cancer companies and academics that are working to assess challenges and seek opportunities that could influence Pancreatic Cancer R&D. The Pancreatic Cancer pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To explore more information on the latest breakthroughs in the Pancreatic Cancer Pipeline treatment landscape of the report, click here @ Pancreatic Cancer Pipeline Outlook

 

Pancreatic Cancer Overview

Pancreatic cancer is a disease in which malignant or cancer cells form in the tissues of the pancreas. Pancreatic cancer begins in the tissues of the pancreas – an organ in the abdomen that lies behind the lower part of the stomach. Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia (PanIN), the classic pre-neoplastic lesions, but can also arise from larger precursor lesions, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms.

 

Pancreatic Cancer Emerging Drugs

 

  • NIS793: Novartis AG

NIS793 is a fully human anti-TGF-β IgG2 monoclonal antibody designed to inhibit the TGF-β pathway in tumor cells and to modulate the tumor microenvironment. In preclinical models, inhibiting TGFβ can reduce fibrosis characteristic of pancreatic and other solid tumor types, as well as enhance the response to chemotherapy and immunotherapy. NIS793 has shown proof of mechanism and acceptable safety profile in a first in-human trial in patients with advanced solid tumors and is in development for pancreatic cancer and other solid tumor types. Currently, the drug is in Phase III stage of its development for the treatment of pancreatic cancer.

 

  • Devimistat: Cornerstone Pharmaceuticals

CPI-613 (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. Cancer progresses because it utilizes the mitochondria – the energy machinery of the cells – to generate the building blocks of the next tumor in order to fuel cancer growth and proliferation. Because it is designed to be highly specific, minimally toxic and effective against a wide variety of cancers, devimistat can be used for recurrent and hard-to-treat cancers, including on a chronic basis; it may also enhance the sensitivity of cancer cells to other treatment modalities, including chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of pancreatic cancer.

 

  • Masitinib: AB Science

Masitinib is a highly selective inhibitor of mast cell which gives therapeutic benefit by impacting on mast cell related remodeling of the tumor microenvironment. Masitinib is being developed in combination with chemotherapies for treatment of malignancies through its immunotherapeutic properties. The increased mast cell activity within the tumor microenvironment can promote disease progression through release of numerous pro-tumoral mediators, down-regulate the immune response to tumors, and modulation of macrophages towards a pro-tumoral state. The inhibition of the mast cell activity results in anti-tumor effect.

 

  • SBP-101: Panbela Therapeutics

Ivospemin (SBP-101) is a proprietary polyamine analogue that, due to its unique chemical structure. It inhibits both S-adenosylmethionine decarboxylase 1 (AMD1) and ornithine decarboxylase 1 (ODC1), two key enzymes in polyamine biosynthesis, lowering intracellular polyamine concentrations and slowing or preventing targeted cell growth and division. Ivospemin provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity. The polyamine pathway at complementary junctions alter the disease. In particular, the drug have the potential to suppress and prevent tumor growth, enhance anti-tumor activity of other anti-cancer agents, and modulate the immune system. Currently, the drug is in Phase II/III stage of its development for the treatment of pancreatic cancer.

 

  • TAS-102: Taiho Pharmaceutical Co., Ltd.

TAS-102 (Lonsurf) is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines. FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase. The drug is currently in Phase II trial for the pancreatic cancer.

 

  • RAIN-32: Rain Oncology

RAIN-32 (Milademetan), an oral small molecule, inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, and loss of an MDM2 regulator or other mechanism. The company commenced an additional Phase II trial in a multicenter, single arm, open-label, and basket trial evaluating milademetan for the treatment of MDM2-amplified advanced solid tumors (MANTRA-2) including pancreatic cancer.

 

  • IMX-110: Immix Biopharma

IMX-110 is a Tissue-Specific Therapeutic™ built on ImmixBio’s TME Normalization™ Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor micro-environment, or TME. ImmixBio’s TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumor blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumor-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumor and its metabolic and structural support. IMX-110’s TME Normalization Technology causes tumor apoptosis, a non-inflammatory tumor-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).

 

IMX-110 is currently being evaluated in a Phase Ib/IIa open-label, dose-escalation/dose-expansion safety, tolerability and pharmacokinetic study in patients with advanced solid tumors in the United States and Australia.

 

For further information, refer to the detailed Pancreatic Cancer Unmet Needs, Pancreatic Cancer Market Drivers, and Pancreatic Cancer Market Barriers, click here for Pancreatic Cancer Ongoing Clinical Trial Analysis

 

Pancreatic Cancer Pipeline Therapeutics Assessment

There are approx. 290+ key companies which are developing the therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, Novartis.

 

Pancreatic Cancer Pipeline Segmentation

 

Phases

DelveInsight’s report covers around 300+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Request a sample and discover the recent advances in Pancreatic Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Pancreatic Cancer Treatment Landscape

 

Scope of the Pancreatic Cancer Pipeline Report

 

  • Coverage- Global

 

  • Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others

 

  • Pancreatic Cancer Pipeline Therapies- Pembrolizumab, Talazoparib, ODM-208, ZEN 3694, EPI-7386, RV 001, Adavosertib, Capivasertib, ADXS31-142, TRC253, Nivolumab, LAE001, BR55, ARV-110, Tazemetostat, REGN5678, VERU-111, Abemaciclib, Cabozantinib, LY01005, Tarlatamab, VT-464, BAY2315497, NX-1207, MBM-02, TAVT-45, FOR46, JNJ-78278343, 64Cu-SAR-bisPSMA, DKN-01, HC-1119, ChAdOx1-MVA 5T4, Onvansertib, GT0918, TNB-585, JANX007, 225Ac-PSMA I&T, CRB-701, BXCL701, AsiDNA, ADXS-504, HB-300, NUV-868, ARX517, JMKX002992, Zilovertamab, IMU-935, BNT112, and others.

 

  • Pancreatic Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Pancreatic Cancer Market Drivers and Pancreatic Cancer Market Barriers, click here @ Pancreatic Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pancreatic Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pamrevlumab: FibroGen
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Niraparib: Innovent Biologics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. CT041: CARsgen Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ONC 212: Oncoceutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pancreatic Cancer Key Companies
  21. Pancreatic Cancer Key Products
  22. Pancreatic Cancer- Unmet Needs
  23. Pancreatic Cancer- Market Drivers and Barriers
  24. Pancreatic Cancer- Future Perspectives and Conclusion
  25. Pancreatic Cancer Analyst Views
  26. Pancreatic Cancer Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Pancreatic Cancer Mergers and acquisitions, Pancreatic Cancer Licensing Activities @ Pancreatic Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services